XML 70 R53.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Segment Reporting Information, by Segment


	Fiscal Year Ended December 31, 2025
	Medical		Nuclear & Safety		Total

Revenues	$	310.8	$	614.6	$	925.4
Less:
Adjusted cost of revenues1	109.0		324.0		433.0
Other segment items2	154.9		189.5		344.4
Segment income from operations	$	46.9	$	101.1	$	148.0
Other loss3					(96.5)
Income from operations					51.5
Less other expense (income):
Interest expense					42.2
Interest income					(12.1)
Loss on debt extinguishment					5.8
Foreign currency (gain)/loss, net					(17.4)
Other income, net					0.3
Consolidated income before income taxes					$	32.7


	Fiscal Year Ended December 31, 2024
	Medical		Nuclear & Safety		Total

Revenues	$	299.7	$	561.1	$	860.8
Less:
Adjusted cost of revenues1	108.7		300.4		409.1
Other segment items2	168.7		181.8		350.5
Segment income from operations	$	22.3	$	78.9	$	101.2
Other loss3					(76.4)
Income from operations					24.8
Less other expense (income):
Interest expense					57.9
Interest income					(6.6)
Foreign currency (gain)/loss, net					2.2
Increase in fair value of warrant liabilities					5.3
Other income, net					(0.1)
Consolidated loss before income taxes					$	(33.9)


	Fiscal Year Ended December 31, 2023
	Medical		Nuclear & Safety		Total

Revenues	$	284.5	$	516.4	$	800.9
Less:
Adjusted cost of revenues1	107.3		289.6		396.9
Other segment items2	164.2		180.8		345.0
Segment income from operations	$	13.0	$	46.0	$	59.0
Other loss3					(80.9)
Loss from operations					(21.9)
Less other expense (income):
Interest expense					61.9
Interest income					(4.8)
Loss on debt extinguishment					2.6
Foreign currency (gain)/loss, net					(0.3)
Increase in fair value of warrant liabilities					24.8
Other income, net					(0.8)
Consolidated loss before income taxes					$	(105.3)


1			Adjusted cost of revenues is a significant expense category, and amounts align with the segment-level information that is regularly provided to the CODM. Adjusted cost of revenues is defined by management as cost of revenues adjusted for purchase accounting impacts and excluding depreciation, amortization, and other segment expenses identified as non-operating by management.
2			Other segment items included in segment income (loss) from operations for each segment include research and development expenses; selling and marketing expenses; general and administrative expenses; and any amounts excluded from cost of revenues to determine adjusted costs of revenues (e.g., depreciation, amortization, and other segment expenses identified as non-operating by management).
3			Other loss consists of research and development expenses; selling and marketing expenses; and general and administrative expenses not allocated to the segments.

The Company’s assets by reportable segment were not included, as this information is not reviewed by, nor otherwise provided to, the CODM to make operating decisions or allocate resources.

The following table summarizes capital expenditures and depreciation and amortization for each reportable segment (in millions).


	Fiscal Year Ended December 31, 2025		Fiscal Year Ended December 31, 2024		Fiscal Year Ended December 31, 2023
Capital expenditures
Medical	$	20.2	$	27.8	$	21.8
Nuclear & Safety	18.7		17.7		18.0
Total operating and reportable segments	38.9		45.5		39.8
Corporate and other	0.7		3.3		1.0
Total capital expenditures	$	39.6	$	48.8	$	40.8
Depreciation and amortization
Medical	$	65.5	$	73.0	$	75.2
Nuclear & Safety	71.6		76.7		86.9
Total operating and reportable segments	137.1		149.7		162.1
Corporate and other	1.0		0.7		0.7
Total depreciation and amortization	$	138.1	$	150.4	$	162.8

Schedule of Revenue from External Customers by Geographic Areas

The following details revenues by geographic region. Revenues generated from external customers are attributed to geographic regions through sales from site locations (i.e. point of origin) (in millions).


	Revenues
	Fiscal Year Ended December 31, 2025		Fiscal Year Ended December 31, 2024		Fiscal Year Ended December 31, 2023
North America
Medical	$	279.3	$	271.9	$	258.1
Nuclear & Safety	302.9		270.3		254.2
Total North America	582.2		542.2		512.3
Europe
Medical	31.5		27.8		26.4
Nuclear & Safety	296.1		277.8		245.7
Total Europe	327.6		305.6		272.1
Asia Pacific
Medical	—		—		—
Nuclear & Safety	15.6		13.0		16.5
Total Asia Pacific	15.6		13.0		16.5
Total Revenues	$	925.4	$	860.8	$	800.9

Schedule of Revenue by Timing of Recognition

The following details revenues by timing of recognition (in millions):


	Revenues
	Fiscal Year Ended December 31, 2025		Fiscal Year Ended December 31, 2024		Fiscal Year Ended December 31, 2023
Point in time	$	620.2	$	567.0	$	496.0
Over time	305.2		293.8		304.9
Total revenues	$	925.4	$	860.8	$	800.9

Schedule of Revenue from External Customers by Products and Services

The following details revenues by product for each segment (in millions). The Company updated the categorization of its products to better align with the markets driving demand. The revenues by product information has been recast for all prior periods presented.


	Revenues
	Fiscal Year Ended December 31, 2025		Fiscal Year Ended December 31, 2024		Fiscal Year Ended December 31, 2023
Medical segment:
Cancer care	$	237.0	$	228.1	$	215.9
Other	73.8		71.6		68.6
Nuclear & Safety segment:
Nuclear	374.6		316.6		291.8
Labs and research	122.2		131.7		122.9
Other	117.8		112.8		101.7
Total Revenues	$	925.4	$	860.8	$	800.9

Schedule of Property, Plant, and Equipment by Geographical Areas

The following details property, plant, and equipment, net, by geography (in millions):


	Property, Plant, and Equipment, Net
	December 31, 2025		December 31, 2024
North America	$	93.4	$	91.5
Europe	61.4		54.7
Asia Pacific	0.1		0.1
Total	$	154.9	$	146.3